Consolidated Statements of Income (Loss) - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Product revenues, net	$ 12,001,300,000	$ 11,020,100,000	$ 9,869,200,000
Costs and expenses:
Cost of sales	1,651,300,000	1,530,500,000	1,262,200,000
Research and development expenses	3,909,500,000	3,630,300,000	3,162,900,000
Acquired in-process research and development expenses	133,000,000.0	4,628,400,000	527,100,000
Selling, general and administrative expenses	1,753,100,000	1,464,300,000	1,136,600,000
Intangible asset impairment charge	379,000,000.0	0	0
Change in fair value of contingent consideration	2,100,000	(500,000)	(51,600,000)
Total costs and expenses	7,828,000,000	11,253,000,000	6,037,200,000
Income (loss) from operations	4,173,300,000	(232,900,000)	3,832,000,000
Interest income	490,900,000	598,100,000	614,700,000
Interest expense	(13,300,000)	(30,600,000)	(44,100,000)
Other expense, net	(7,700,000)	(86,100,000)	(22,800,000)
Income before provision for income taxes	4,643,200,000	248,500,000	4,379,800,000
Provision for income taxes	690,000,000.0	784,100,000	760,200,000
income (loss)	$ 3,953,200,000	$ (535,600,000)	$ 3,619,600,000
Net income (loss) per common share:
Basic (in dollars per share)	$ 15.46	$ (2.08)	$ 14.05
Diluted (in dollars per share)	$ 15.32	$ (2.08)	$ 13.89
Shares used in per share calculations:
Basic (in shares)	255.7	257.9	257.7
Diluted (in shares)	258.0	257.9	260.5
Product revenues, net
Product revenues, net	$ 11,970,600,000	$ 11,020,100,000	$ 9,869,200,000
Other revenues
Product revenues, net	$ 30,700,000	$ 0	$ 0